top of page

AMRN ANDA patent litigation: Key Considerations for Investors

  • Writer: BPIQ
    BPIQ
  • Nov 21
  • 1 min read

Experienced PhD biotech patent attorney and biopharma investor, Manny Vacchiano, discusses some key points and events in the appeal of the district court obviousness ruling of the AMRN ANDA litigation, and discusses the #1 misconception of investors with respect to the asserted patents.

Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page